Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.64 |
| ▸ | SERPINC1 | P01008 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | BDNF | P23560 | 3/20 | 0.46 |
| ▸ | PTN | P21246 | 2/20 | 0.46 |
| ▸ | MDK | P21741 | 2/20 | 0.46 |
| ▸ | FGF1 | P05230 | 2/20 | 0.42 |
| ▸ | FGF2 | P09038 | 1/20 | 0.42 |
| ▸ | CXCL12 | P48061 | 3/20 | 0.42 |
| ▸ | CCL2 | P13500 | 2/20 | 0.42 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.42 |
| ▸ | CCL5 | P13501 | 1/20 | 0.42 |
| ▸ | BMP2 | P12643 | 2/20 | 0.38 |
| ▸ | VEGFA | P15692 | 2/20 | 0.38 |
| ▸ | SHH | Q15465 | 2/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 6/20 | 0.38 |
| ▸ | PF4 | P02776 | 2/20 | 0.37 |
| ▸ | IFNG | P01579 | 1/20 | 0.37 |
| ▸ | SELP | P16109 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4593793 | 1.00 | F10 (0.64) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL14670002 | 1.00 | F10 (0.64) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL15416845 | 0.91 | F10 (0.57) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL30006146 | 0.91 | F10 (0.57) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL23337007 | 0.90 | F10 (0.64) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL29308178 | 0.89 | F10 (0.79) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL23135895 | 0.89 | F10 (0.62) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL16509456 | 0.86 | F10 (0.77) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL15417563 | 0.85 | F10 (0.53) | F10SERPINC1F2BDNFPTN | |
| SCHEMBL27448112 | 0.84 | BDNF (0.60) | F10SERPINC1F2BDNFPTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240219372-A1 | ANALYTICAL METHOD FOR GLYCOSAMINOGLYCANS | JCR PHARMACEUTICALS CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| CN-110475545-B | Injectable and biodegradable polymeric formulations for the controlled release of bioactive agents | W.L.戈尔及同仁股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-109459503-B | Method for measuring weight average molecular weight and content of heparin drugs | 上海绿谷制药有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115814202-A | Medical delivery device with inhibited oxygen permeation | W.L.戈尔及同仁股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-112312946-B | Medical delivery device with inhibited oxygen permeation | W.L.戈尔及同仁股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| CN-110325235-B | Medical delivery device with low lubrication syringe barrel | W.L.戈尔及同仁股份有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-112805016-A | Matrix-binding vesicles (MBVs) comprising IL-33 and uses thereof | 联邦高等教育系统匹兹堡大学 | 2021-05-14 | — | — | CN | disclosed |
| CN-112657021-A | Drug delivery device with a laminated plug | W.L.戈尔及同仁股份有限公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-112603895-A | Freeze-drying process preparation method of dalteparin sodium | 江苏万邦生化医药集团有限责任公司 | 2021-04-06 | — | — | CN | disclosed |
| US-20190134211-A1 | CAR PEPTIDE FOR HOMING, DIAGNOSIS & TARGETED THERAPY FOR PULMONARY AND FIBROTIC DISORDERS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2019-05-09 | — | — | US | disclosed |
| CN-103232558-B | Preparation method of high-quality low-molecular weight dalteparin sodium | SHANDONG CHENZHONG BIOPHARMACEUTICAL CO LTD | 2015-04-22 | — | — | CN | disclosed |
| US-8513188-B2 | Formulations comprising cyclic compounds | CAPSUGEL BELGIUM (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | CAPSUGEL BELGIUM (BE) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | SLC2A1, SLC2A4, SLC2A9 | F10 372/4885SERPINC1 1472/4885F2 2277/4885 |
| US-20190134211-A1 | CAR PEPTIDE FOR HOMING, DIAGNOSIS & TARGETED THERAPY FOR PULMONARY AND FIBROTIC DISORDERS | CXCL12, CCL2, CCR9 | F10 3355/4885SERPINC1 1091/4885F2 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.